Roles of Changes in Active Glutamine Transport in Brain Edema Development During Hepatic Encephalopathy: An Emerging Concept by Magdalena Zielińska et al.
OVERVIEW
Roles of Changes in Active Glutamine Transport in Brain Edema
Development During Hepatic Encephalopathy: An Emerging
Concept
Magdalena Zielin´ska • Mariusz Popek •
Jan Albrecht
Received: 14 June 2013 / Revised: 20 August 2013 / Accepted: 22 August 2013 / Published online: 26 September 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Excessive glutamine (Gln) synthesis in
ammonia-overloaded astrocytes contributes to astrocytic
swelling and brain edema, the major complication of
hepatic encephalopathy (HE). Much of the newly formed
Gln is believed to enter mitochondria, where it is recycled
to ammonia, which causes mitochondrial dysfunction (a
‘‘Trojan horse’’ mode of action). A portion of Gln may
increase osmotic pressure in astrocytes and the interstitial
space, directly and independently contributing to brain
tissue swelling. Here we discuss the possibility that altered
functioning of Gln transport proteins located in the cellular
or mitochondrial membranes, modulates the effects of
increased Gln synthesis. Accumulation of excess Gln in
mitochondria involves a carrier-mediated transport which
is activated by ammonia. Studies on the expression of the
cell membrane N-system transporters SN1 (SNAT3) and
SN2 (SNAT5), which mediate Gln efflux from astrocytes
rendered HE model-dependent effects. HE lowered the
expression of SN1 at the RNA and protein level in the
cerebral cortex (cc) in the thioacetamide (TAA) model of
HE and the effect paralleled induction of cerebral cortical
edema. Neither SN1 nor SN2 expression was affected by
simple hyperammonemia, which produces no cc edema.
TAA-induced HE is also associated with decreased
expression of mRNA coding for the system A carriers
SAT1 and SAT2, which stimulate Gln influx to neurons.
Taken together, changes in the expression of Gln
transporters during HE appear to favor retention of Gln in
astrocytes and/or the interstitial space of the brain. HE may
also affect arginine (Arg)/Gln exchange across the astro-
cytic cell membrane due to changes in the expression of the
hybrid Arg/Gln transporter y?LAT2. Gln export from brain
across the blood–brain barrier may be stimulated by HE via
its increased exchange with peripheral tryptophan.
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Gln Accumulation as a Cause of Astrocytic Swelling
and Brain Edema in HE: A Brief Overview
Hepatic encephalopathy (HE) is a complex neuropsychiatric
syndrome caused by liver failure where excessive accumu-
lation of blood-derived ammonia in the brain is a primary
causative factor. Acute HE or aggravation of a chronic
condition due to hyperammonemic incidents is associated
with brain edema, which often leads to the patients’ death in
consequence of increased intracranial pressure and hernia-
tion (reviewed in [1, 2]). Brain edema is primarily cytotoxic
in nature and is mainly due to astrocytic swelling (AS [1]).
The current view is that excessive synthesis of Gln from
ammonia and glutamate catalyzed by an astrocyte-specific
enzyme, glutamine synthetase (GS) plays a major role in the
pathogenesis of AS. The natural history of this view has been
exhaustively described in recent review articles [3, 4].
Briefly, the concept originates from the observation that Gln
in cultured astrocytic increases oxidative stress in 6-diazo-5-
oxo–L-norleucine (DON), histidine (His) and cyclosporine
A-sensitive manner. It has also been shown that HE in
experimental animals subside or became attenuated upon
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treatment with a GS inhibitor, methionine sulfoximine
(MSO). The abnormalities in the brain corrected by MSO
include, among other events, decreased oxygen consumption
and large neutral amino acid imbalance [5], and, at the
physiological level, decreased specific gravity and/or
increased water content of the tissue, reflecting brain edema
[6, 7]. At the cellular level, MSO reduces perivascular
astrocytic and pericytic swelling in cerebral cortex (cc) of
hyperammonemic rats [8, 9], and swelling of cultured
astrocytes exposed to ammonia [10]. The toxic effects of Gln
are believed to be largely due to its entry to mitochondria and
subsequent intra-mitochondrial release of toxic concentra-
tions of ammonia, which leads to mitochondrial permeability
transition (mPT) and swelling [11]. This sequence of events
has been derived from in vitro studies and has been sum-
marized as the ‘‘Trojan horse’’ hypothesis [3]. According to
this hypothesis, Gln acting as a ‘‘Trojan horse’’ would con-
tribute to other actions of ammonia at different cellular tar-
gets, collectively resulting in the complex interplay of
oxidative/nitrosative stress and impairment of in- and out-
transport of different osmolytes, leading to intracellular
osmotic imbalance [12, 13]. However, the Trojan horse
hypothesis still needs to be unequivocally validated in the
in vivo setting. One of the weak points of the hypothesis is
related to the controversy whether glutamine is located in the
inner mitochondrial membrane or in the inter-membrane
space as suggested by Kvamme et al. [14]. Independently,
accumulation of Gln is believed to directly contribute to the
osmotic imbalance in astrocytes [15].
While part of newly accumulated Gln may passively dif-
fuse from the locus of its synthesis, its considerable fraction is
directed towards different destinations by active transport
mediated by specific carriers. The present paper addresses the
as yet unresolved question whether and in what degree mod-
ulation of the carriers by the pathogenic condition affects the
Gln-related pathogenesis. In the following section we provide
basic information about how Gln is shuttled between the cells
and subcellular compartments of the brain and how it manages
to egress the brain to the periphery.
Gln Transport in the CNS
Mitochondrial Gln Transport
Cerebral mitochondria possess an active, saturable trans-
port system for Gln. The system operates at relatively high
affinity and low capacity and is therefore well suited for the
regulation of the entry of Gln from cytoplasm, where it is
present at low milimolar concentrations [16]. Mitochon-
drial Gln uptake is inhibited by several neutral amino acids,
of which histidine (His) appears to exert the strongest
inhibitory effect [17].
Gln Transport in Astrocytes and Neurons
Gln transporting proteins are present both in astrocytes and
neurons, but are distributed between them asymmetrically.
Astrocytes are enriched in two bi-directional system N
transporters: SN1 [18] and SN2 [19]. SN1 is the best
candidate to specifically mediate Gln efflux from astro-
cytes. SN1 has an activity optimum at physiological
extracellular Gln concentration (Km *0.4 mM) and shows
independence on a substrate on the trans-side, which pre-
disposes it to be a mediator of net efflux [18]. Furthermore,
SN1 activity is positively controlled by intracellular Glu
[20], and the significance of this interdependence is
underscored by the fact that neuron-derived neurotrans-
mitter Glu accounts for *80–90 % of the substrate pool
for Gln synthesis in astrocytes [21]. SN2 is less ubiquitous
in the CNS than SN1 and in addition to Gln release,
mediates glycine release for regulation of the N-methyl-D-
aspartate (NMDA) receptor function [22]. Still, the precise
role of each of the two transporters in regulating Gln efflux
from astrocytes and its distribution in the different com-
partments of the CNS is not completely clear as yet. In
neurons, Gln uses as carriers two neuronal system A
transporters: SAT1 and SAT2, of which SAT2 specifically
serves to replenish Glu in glutamatergic neurons [23]. Part
of Gln migrates between the different cellular compartment
in exchange for arginine (Arg), using the y?L system. The
y?L system is represented by 4F2hc/y?LAT1 and 4F2hc/
y?LAT2 transporters, which in addition to cationic amino
acids accept neutral amino acids; the transport of the latter
is coupled to Na? [24]. Of these two transporters, the brain
expresses only y?LAT2 [25, 26], which appears to abound
in astrocytes and as such is well suited for catalyzing Gln/
Arg exchange in these cells [27].
Gln Transport in the Blood–Brain Barrier-Forming
Cerebral Capillary Endothelial Cells
Available evidence suggests that Gln transport at the
blood–brain barrier (BBB) is primarily mediated by system
N transporters [18, 28]. Studies with luminal and abluminal
plasma membrane vesicles derived from bovine brain
endothelial cells disclosed that system N transporters
account for *80 % of Gln transport from brain to
peripheral blood [29], and the presence of SN1 in the
endothelial cells has been well documented [30]. Gln out-
transport from the brain is also facilitated by system
L-mediated exchange with other large neutral amino acids,
mainly tryptophan (Try) [31, 32]. The Arg/Gln exchanger
y?LAT2 appear to be likewise expressed in the cerebral
capillary endothelial cells in culture, but much less so
in situ [33].
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Effects of HE on Gln Transport in the Brain
and Expression of Transporters Residing
in the Different Compartments: State of the Art
Gln Uptake in Brain Slices
HA [3 i.p. injections of ammonium acetate (600 mg per kg)
at 24 h intervals] decreased L-[3H] Gln uptake to the
cerebral cortical slices, and the decrease affected the
component of uptake sensitive to leucine (Leu), 2-amino-
bicyclo(2,2,1)heptane-2-carboxylic acid (BCH), and cyclo-
leucine, indicating selective vulnerability to system L
(Fig. 1).
Mitochondria
Convincing evidence that transport of excess of newly
formed Gln to brain mitochondria is carrier-mediated has
come from studies analyzing the effects of the transport
competitor, His. Co-incubation with His abolished Gln-
evoked mPT and swelling, and the response was well
correlated with inhibition of Gln uptake [34]. His inhibited
swelling of ammonia-treated astrocytes and the effect
showed cooperativity with MSO [35]. His administered i.p.
attenuated brain edema and other oxidative stress-related
responses in the brain in rats with thioacetamide (TAA)-
induced HE [36]. However, results obtained with His must
be interpreted with caution do to its pleiotropic effects,
including direct amelioration of HE-induced oxidative
stress, as manifested by the recovery of mitochondrial
glutathione [37], and, independently of the tissue status,
interference with system N-mediated Gln transport at the
astrocytic cell membranes [38], and references therein). An
earlier observation indicated that ammonia increases Gln
uptake to non-synaptic (astrocytic) mitochondria [39],
which is likely to augment the mitochondrial effects of
excess Gln in the setting of HE, where brain ammonia is
elevated as a rule [2, 32].
Astrocytes and Neurons
Experiments carried out in this laboratory demonstrated a
marked decrease of SN1 and SN2 expression at the mRNA
and SN1 at the protein level, in the cc of rats with TAA-
induced HE (Fig. 2a, b), coinciding with marked cc swelling
in this model [40]. Interestingly, SN1 and SN2 expression
remained unaltered in rats with simple hyperammonemia
(HA) in the ammonium acetate model (Fig. 3a, b), where
(cc) does not change its volume [40]. Two other groups have
measured the effects of HE on SN2 mRNA expression in two
different models. Our results are in agreement with
decreased SN2 mRNA expression in the acute liver failure
(azoxymethane) model in mice reported by Desjardins et al.
[41]. The results of the present study are also compatible with
the unchanged expression of SN2 protein in the mice TAA
model similar to our model, as revealed immunocytochem-
ically [42]. It must be reemphasized, however that, SN1 but
not SN2 is believed to be the key mediator of the efflux of
newly synthesized Gln from astrocytes [38].
A variable response of the y?LAT2 carrier has been
noted in the two different models. Simple hyperammonemia
(HA) stimulated the expression of y?LAT2 mRNA and
protein in the brain, accounting for an increased back-flux
of Gln to the cells (probably astrocytes) on the expense of
Arg [27]. HE in the TAA model decreased the brain
y?LAT2 expression at the mRNA level, leaving the
y?LAT2 protein unchanged (Fig. 2a, b). The ambiguity of
the responses noted, and the impact of the observed changes
on the overall tissue balance of Gln remain to be clarified.
Transport Across the BBB
The effect of HE or ammonia on the system N-mediated
Gln transport in the cerebral capillary endothelial cells has
not been examined as yet. The L system-dependent
exchange of systemic Try with intracerebral Gln has been
found increased in cerebral capillary endothelial cells
treated with ammonia [31], or isolated from rats with HE
[32]. While the results tend to support increased efflux of
newly formed Gln from the brain to the periphery in the
setting of HE, the significance of the observation cannot be
appreciated before its role relative to the system N-medi-
ated transport is unraveled. Ammonia also increased
y?LAT2 expression in the cerebral capillary endothelial
Fig. 1 Effect of the presence of 10 mM BCH, Leu and cyclo-Leu on
[3H] Gln uptake in control and hyperammonemic (HA) rat cerebral
cortical slices. Cerebral cortical slices of HA rat were pre-incubated
for 30 min at 37 C and the uptake was started by adding L-[3H] Gln
(Perkin-Elmer) at 100 mmol/l final concentration and the incubation
was continued for 4 min. The incubation was terminated by rapid
vacuum filtration, followed by three washes with 2 ml with Krebs
buffer maintained at 4 C. The radioactivity on filter disks was
measured in a liquid scintillation spectrometer. The control value for
[3H] Gln uptake was 29.5 nmol/min/mg wet tissues. Values in each
group are mean ± SD for n = 5. (*p \ 0.05; Dunnet’s test)
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cell line [43], but how this increase translates into Gln/Arg
exchange and whether, and in what degree, it is eventually
reflected in the tissue distribution of Gln is unknown.
Conclusions and Perspectives
Collectively, the above presented data suggest that HE-
induced alterations in the expression of the Gln transport-
ing proteins may favor Gln trapping within the vulnerable
compartments of the brain. According to the most plausible
scenario, decreased expression of the astrocytic Gln
transporters SN1 (SNAT3) and SN2 (SNAT5), if translated
into their decreased activity (this presumption remains to
be tested), will impair Gln efflux from astrocytes. This in
turn will lead to increased intra-astrocytic and in conse-
quence, intra-mitochondrial accumulation of Gln, the latter
process being additionally stimulated by ammonia-induced
activation of the mitochondrial Gln carrier. This sequence
of mutually amplifying events would contribute to astro-
cytic swelling both by the cytoplasmic—osmotic mecha-
nism, and by the mitochondrial—Trojan horse model.
A question that remains to be resolved is how to rec-
oncile the elevation of intraastrocytic Gln content with the
increase of extracellular Gln, frequently observed in HE
[15, 44, 45]. One possible explanation would be that the
apparent increase of extracellular Gln concentration is due
to the shrinkage of extracellular space subsequent to
astrocytic swelling, as earlier suggested for the increased
accumulation of extracellular K? in the brains of hyper-
ammonemic rats [46]; in such a case, however, the increase
would encompass, in a nonselective way, other amino acids
as well. One other possibility would be a decreased back-
flux of Gln to astrocytes, due to an unfavorable concen-
tration gradient. Clearly, further work is needed to resolve
between these two possibilities.
Consequences of the decreased expression of the neu-
ronal transporters SAT1 and SAT2 are more difficult to
Fig. 2 a, b Expression of SN1, SN2 and y?LAT2 at the mRNA
(a) and protein (b) level in cerebral cortex of control rats and rats with
TAA-induced HE. a Relative quantification of SN1, SN2, y?LAT2
mRNA. Total RNA was isolated using TRI Reagent (Sigma-Aldrich),
and reverse-transcribed using High Capacity cDNA Reverse Tran-
scribed Kit (Life Technologies; Applied Biosystems). Probes for SN1,
SN2, y?LAT2 and b-actin (Rn 01447660, Rn 00684896, Rn
01431908_m1 and Rn 00667869, respectively) were purchased from
Applied Biosystems. Further details were as described in Ref. [27].
Values in each group are mean ± SD for n = 8; *p \ 0.05; T test.
b Quantification of SN1, SN2, y?LAT2 protein densities. The
antibodies used included SN1 (Santa Cruz Biotechnology; goat
polyclonal, 1:500), SN2 (Santa Cruz Biotechnology; goat polyclonal,
1:1,000), y?LAT2 (Santa Cruz Biotechnology; 1:1,000, rabbit
polyclonal) and GAPDH (Sigma-Aldrich; rabbit polyclonal,
1:3,000). Representative immunoblots of SN1, SN2, y?LAT2 and
GAPDH (loading control) corresponding to the immunoblots of
transporters. See Ref. [27] for further experimental details. Values in
each group are mean ± SD for n = 5–8. (*p \ 0.05; T test)
Fig. 3 a, b Expression of SN1 and SN2 at the mRNA (a) and protein
(b) level in cerebral cortex of control rats and rats with ammonium
acetate-induced HA. Values in each group are mean ± SD for n = 4
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predict. If a portion of Gln newly derived from astrocytes
indeed ‘‘omits’’ neurons, this may either lead to increased
Gln efflux across the BBB, or contribute to its increased
trapping in the extracellular space. The latter interpretation
would be consistent with the earlier discussed increase of
extracellular Gln often recorded in human HE patients [15]
and animal HE models [44, 45].
Clearly, interpretations of the results derived so far will
have to be verified by detailed investigation on how the
changes expression of the different Gln-transporting moi-
eties are translated into their functional status. While pre-
liminary data obtained in this laboratory demonstrate that
ammonia, the key primary cause of astrocytic swelling
does inhibit Gln uptake in vitro (Fig. 1), the inhibition
appears to primarily involve the sodium-independent L
system, which does not appear compatible with the trans-
porter expression data. However, the complexity of cellular
composition of the slice and the ensuing difficulty to ana-
lyze the contribution of the different cell components to the
final result, do not permit simple extrapolation of the
results obtained in vitro to the in vivo conditions. Assess-
ment of the role of alterations in Gln transport in the
redistribution of Gln overload between the different com-
partments of the CNS will not be possible without
knowledge is acquired about quantitative contribution of
active transport and diffusion to Gln fluxes. To this end,
Gln fluxes will have to be compared in the brains of normal
rats and rats with selectively inactivated transporters
(knockout animals, siRNA), using the NMR technique.
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